Peptic Ulcers & the Gut Microbiome: Beyond H. pylori

Overview

Peptic ulcer disease (PUD) encompasses open sores that develop on the inner lining of the stomach (gastric ulcers) and the upper portion of the small intestine (duodenal ulcers). Globally, approximately 5-10% of people will develop a peptic ulcer during their lifetime, with the condition accounting for significant morbidity, healthcare costs, and, in cases of perforation or hemorrhage, mortality.^[1] The two most well-established causes are Helicobacter pylori infection and chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), which together account for the majority of cases.

However, an important and often overlooked fact is that a substantial proportion of peptic ulcers -- estimated at 20-25% in some populations -- arise without either H. pylori infection or NSAID exposure, a category known as idiopathic peptic ulcers.^[2] This observation has driven researchers to look beyond H. pylori alone and consider the broader microbial ecosystem of the stomach and duodenum. While H. pylori pathogenesis is covered in depth on our H. pylori Gastritis page, this article focuses on the wider microbiome landscape that influences ulcer formation, mucosal defense, and healing.

The relationship between peptic ulcers and gastroesophageal reflux disease (GERD) is also clinically relevant: both conditions involve disruptions to the upper gastrointestinal mucosa, share overlapping risk factors including PPI use and microbial imbalance, and may coexist in the same patient.

Key Takeaways

• The gastric microbiome extends well beyond H. pylori, and shifts in non-H. pylori communities may influence ulcer susceptibility and healing
• NSAIDs disrupt protective commensal bacteria in the stomach and small intestine, compounding their direct mucosal toxicity
• Proton pump inhibitors (PPIs) alter gastric and intestinal microbial composition in ways that may affect ulcer recurrence risk
• Probiotic supplementation during H. pylori eradication therapy may reduce antibiotic side effects by 40-60% and modestly improve cure rates
• Idiopathic ulcers -- those without H. pylori or NSAID involvement -- represent a growing clinical challenge where microbiome research may offer new insights

The Microbiome Connection

The Gastric Microbiome Beyond H. pylori

For decades, the stomach was considered a largely sterile environment due to its harsh acidic conditions. This view has been fundamentally revised. Culture-independent techniques, particularly 16S rRNA gene sequencing, have revealed a diverse gastric microbial community comprising over 100 bacterial species even in healthy individuals. The dominant phyla in the healthy stomach include Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria, with genera such as Streptococcus, Prevotella, Rothia, and Veillonella commonly represented.^[3]

When H. pylori colonizes the stomach, it does not act in isolation. Its presence significantly reshapes the surrounding microbial community, reducing overall diversity and altering the relative abundance of commensal species.^[4] This broader dysbiosis may contribute to ulcerogenesis through mechanisms independent of H. pylori's own virulence factors. Understanding these community-level effects is essential for explaining why some H. pylori-infected individuals develop ulcers while the majority do not.

NSAID-Microbiome Interactions and Mucosal Injury

NSAIDs cause peptic ulcers through well-characterized mechanisms including inhibition of cyclooxygenase (COX) enzymes and disruption of the mucosal prostaglandin barrier. However, emerging evidence suggests that NSAID-induced injury is not purely a pharmacological event -- the gut microbiome plays an active role. In animal models, germ-free mice show significantly less NSAID-induced intestinal damage compared to conventionally colonized animals, indicating that commensal bacteria participate in the injury process.

Conversely, certain protective commensals may buffer against NSAID toxicity. NSAIDs alter the composition of the upper GI microbiome, reducing populations of Lactobacillus and other lactic acid bacteria that contribute to mucosal integrity through production of short-chain fatty acids and maintenance of the mucus layer. The combination of PPIs and NSAIDs -- common in clinical practice -- may be particularly detrimental to the microbiome, as PPIs raise gastric pH and enable colonization by oral and intestinal bacteria not normally adapted to the gastric environment.^[5]

Antibiotic Eradication Therapy and Collateral Microbiome Damage

Standard H. pylori eradication regimens involve 7-14 days of combined antibiotics (typically clarithromycin and amoxicillin or metronidazole) alongside a PPI. While effective against H. pylori, these regimens inflict substantial collateral damage on commensal microbial communities throughout the GI tract. Studies using metagenomic sequencing have documented persistent reductions in microbial diversity lasting months to years after a single course of eradication therapy.^[6]

This collateral dysbiosis is clinically relevant to ulcer patients because it may contribute to antibiotic-associated diarrhea, Clostridioides difficile infection, and potentially delayed mucosal healing. The disruption also raises the question of whether repeated eradication attempts in treatment-resistant cases might further compromise the microbiome environment needed for ulcer recovery. For a detailed discussion of eradication regimens and resistance patterns, see our H. pylori Gastritis guide.

Key Microorganisms

Helicobacter pylori

• Impact: Primary infectious cause of peptic ulcer disease; responsible for the majority of duodenal ulcers and a large proportion of gastric ulcers
• Function: Produces urease to neutralize gastric acid, deploys CagA and VacA virulence factors that directly damage epithelial cells, and triggers chronic inflammatory cascades that weaken the mucosal barrier^[2]

Non-H. pylori Gastric Commensals (Streptococcus, Prevotella, Rothia)

• Impact: Form the core resident community of the healthy stomach; their displacement or reduction is associated with disease states
• Function: May contribute to colonization resistance against pathogens, participate in nitrate metabolism that influences mucosal blood flow, and produce metabolites that support epithelial integrity^[3]

Saccharomyces boulardii

• Impact: The most extensively studied probiotic in the context of H. pylori eradication therapy
• Function: Produces proteases that degrade H. pylori virulence factors, strengthens tight junctions, and reduces antibiotic-associated diarrhea; meta-analyses demonstrate improved eradication rates and significantly reduced side effects when added to standard therapy^[7]

Lactobacillus rhamnosus GG

• Impact: Widely studied for its ability to reduce gastrointestinal side effects during antibiotic therapy
• Function: Competes with pathogenic bacteria for adhesion sites, modulates mucosal immune responses, and may enhance the mucus layer that protects against acid-mediated injury^[8]

Microbiome-Based Management Strategies

Probiotic Adjunct Therapy During Eradication

The most robust evidence for microbiome-based intervention in peptic ulcer disease comes from trials of probiotic supplementation alongside standard H. pylori eradication therapy. A comprehensive meta-analysis of randomized controlled trials found that probiotic supplementation reduced the overall incidence of therapy-associated side effects, particularly diarrhea, nausea, and taste disturbance, while modestly improving eradication success rates.^[8] Saccharomyces boulardii has shown the most consistent benefit, with meta-analytic data supporting an approximately 10% improvement in eradication rates and a significant reduction in antibiotic-associated diarrhea.^[7] Lactobacillus rhamnosus GG and multi-strain formulations have also demonstrated benefits in individual trials, though the evidence is less uniform.

• Evidence Level: Strong -- multiple meta-analyses of RCTs support probiotic use as adjunct therapy for reducing side effects; moderate evidence for improved eradication rates

Mucosal Recovery and Post-Eradication Support

After successful H. pylori eradication, the gastric microbiome does not immediately return to a healthy baseline. The recovery period represents a window during which targeted nutritional and probiotic support may facilitate mucosal healing and prevent ulcer recurrence. Fermented foods containing live cultures, adequate dietary fiber to support SCFA production, and avoidance of gastric irritants (alcohol, tobacco, caffeine on an empty stomach) may complement medical therapy during this phase. Preliminary data suggest that certain probiotic strains may accelerate gastric epithelial regeneration, though dedicated clinical trials in post-ulcer healing are limited.

• Evidence Level: Preliminary -- biological rationale is supported by preclinical data, but clinical evidence specifically for post-ulcer microbiome restoration is emerging

NSAID Risk Mitigation Through Microbiome Support

For patients who require ongoing NSAID therapy, strategies that support the upper GI microbiome may offer an additional layer of protection beyond standard gastroprotective agents like PPIs and misoprostol. Research in animal models suggests that co-administration of certain Lactobacillus strains may reduce NSAID-induced intestinal injury by reinforcing the mucosal barrier and modulating local inflammatory responses.^[5] In practice, patients on chronic NSAIDs who also take PPIs should be aware that the combination may produce compounding microbiome disruption, and periodic reassessment of both medications is warranted.

• Evidence Level: Preliminary -- largely based on preclinical models; human trials specifically examining probiotic protection against NSAID-ulcer risk are needed

Dietary and Lifestyle Approaches

Dietary patterns that promote gastric microbial diversity may support ulcer prevention and healing. A diet rich in fruits, vegetables, and whole grains provides substrates for beneficial microbial metabolism, while polyphenol-rich foods (green tea, berries, cruciferous vegetables) have demonstrated gastroprotective effects in observational studies. Avoidance of excessive alcohol, smoking cessation, and stress management are well-established ulcer prevention strategies that may also support a healthier gastric microbial environment. For patients with overlapping GERD symptoms, dietary modifications that address both acid reflux and gastric microbiome health can serve dual purposes.

• Evidence Level: Moderate for lifestyle factors in ulcer prevention; indirect evidence for microbiome-mediated mechanisms

Future Directions

The peptic ulcer field is moving beyond the binary framework of "H. pylori present or absent" toward a more nuanced understanding of how the entire gastric microbial ecosystem influences disease risk and outcomes. Metagenomic and metabolomic studies are beginning to characterize the functional contributions of non-H. pylori bacteria to mucosal health, potentially explaining why some individuals develop idiopathic ulcers and why ulcer recurrence rates vary widely even after successful eradication.

Personalized approaches to eradication therapy -- selecting antibiotic regimens based on both H. pylori resistance profiles and the patient's baseline microbiome composition -- may improve cure rates while minimizing collateral microbial damage. The development of targeted postbiotics and next-generation probiotics engineered for upper GI colonization could offer novel therapeutic tools for both ulcer prevention and accelerated healing. As the relationship between PPIs, NSAIDs, and the gastric microbiome becomes better defined, clinical guidelines may increasingly incorporate microbiome stewardship principles alongside traditional pharmacological management of peptic ulcer disease.